135 related articles for article (PubMed ID: 34530214)
21. Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.
Liu DH; Zhou XY; Pan YG; Chen S; Ye ZH; Chen GD
Cancer Med; 2020 Feb; 9(4):1287-1297. PubMed ID: 31859464
[TBL] [Abstract][Full Text] [Related]
22. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
Yang H; Chen X; Lin S; Rong J; Yang M; Wen Q; Shang C; He L; Ren P; Xu S; Zhang J; Liu Q; Pang H; Shi X; Fan J; Sun X; Ma D; Tan B; Zhang T; Zhang L; Hu D; Du X; Zhang Y; Wen S; Zhang X; Wu J
Radiother Oncol; 2018 Jan; 126(1):37-42. PubMed ID: 28864073
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of wait time for radical radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
Jiang YT; Chen KH; Yang J; Liang ZG; Qu S; Li L; Zhu XD
Head Neck; 2022 May; 44(5):1182-1191. PubMed ID: 35218120
[TBL] [Abstract][Full Text] [Related]
24. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
Chen FP; Luo YS; Chen K; Li JY; Huo LQ; Shi L; Ou-Yang Y; Cao XP
Eur J Cancer; 2021 Jul; 151():63-71. PubMed ID: 33964573
[TBL] [Abstract][Full Text] [Related]
25. Induction Chemotherapy Followed by Radiotherapy versus Concurrent Chemoradiotherapy in elderly patients with nasopharyngeal carcinoma: finding from a propensity-matched analysis.
Zeng Q; Wang J; Lv X; Li J; Yin LJ; Xiang YQ; Guo X
BMC Cancer; 2016 Aug; 16(1):693. PubMed ID: 27577729
[TBL] [Abstract][Full Text] [Related]
26. Significance of boost dose for T4 nasopharyngeal carcinoma with residual primary lesion after intensity-modulated radiotherapy.
Fei Z; Xu T; Qiu X; Li M; Chen T; Li L; Huang C; Chen C
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2047-2055. PubMed ID: 33392660
[TBL] [Abstract][Full Text] [Related]
27. Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.
Yao JJ; Zhang F; Gao TS; Zhang WJ; Lawrence WR; Zhu BT; Zhou GQ; Ma J; Wang SY; Sun Y
Radiother Oncol; 2019 Mar; 132():178-187. PubMed ID: 30448002
[TBL] [Abstract][Full Text] [Related]
28. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response.
Liu SL; Sun XS; Yan JJ; Chen QY; Lin HX; Wen YF; Guo SS; Liu LT; Xie HJ; Tang QN; Liang YJ; Li XY; Lin C; Du YY; Yang ZC; Xiao BB; Yang JH; Tang LQ; Guo L; Mai HQ
Radiother Oncol; 2019 Aug; 137():83-94. PubMed ID: 31078941
[TBL] [Abstract][Full Text] [Related]
29. Comparing the efficacy of induction-concurrent with concurrent-adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis.
Wu LR; Jiang XS; Song X; Yu HL; Fan YX; Wang FJ; Huang SF; Guo WJ; He X; Liu JY
Oncotarget; 2017 Oct; 8(45):79953-79963. PubMed ID: 29108377
[TBL] [Abstract][Full Text] [Related]
30. The effect of primary tumor volume on the prognosis of nasopharyngeal carcinoma in era of volumetric modulated arc therapy: a propensity score matched cohort study.
Lin X; Wang B; Zheng F; Fei Z; Chen C
Braz J Otorhinolaryngol; 2023; 89(3):374-382. PubMed ID: 37105031
[TBL] [Abstract][Full Text] [Related]
31. Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy.
Li WF; Li YQ; Chen L; Zhang Y; Guo R; Zhang F; Peng H; Sun Y; Ma J
BMC Cancer; 2015 Oct; 15():810. PubMed ID: 26506820
[TBL] [Abstract][Full Text] [Related]
32. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX
Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487
[TBL] [Abstract][Full Text] [Related]
33. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538
[TBL] [Abstract][Full Text] [Related]
34. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M
Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190
[TBL] [Abstract][Full Text] [Related]
35. Geographical disparities in the prognosis of patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: a large institution-based cohort study from an endemic area.
Lin ST; Meng DF; Yang Q; Wang W; Peng LX; Zheng LS; Qiang YY; Mei Y; Xu L; Li CZ; Peng XS; Hu H; Lang YH; Liu ZJ; Wang MD; Li HF; Huang BJ; Qian CN; Sun R
BMJ Open; 2020 Nov; 10(11):e037150. PubMed ID: 33172940
[TBL] [Abstract][Full Text] [Related]
36. Neck level Ib-sparing versus level Ib-irradiation in intensity-modulated radiotherapy for the treatment of nasopharyngeal carcinoma with high-risk factors: A propensity score-matched cohort study.
Wang G; Huang C; Yang K; Guo R; Qiu Y; Li W; Mao Y; Tang L; Ma J
Radiother Oncol; 2022 Dec; 177():205-213. PubMed ID: 36375564
[TBL] [Abstract][Full Text] [Related]
37. The Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio before Radical Radiotherapy in Patients with Non-metastatic Nasopharyngeal Carcinoma: A Propensity Score Matching Analysis.
Kim JS; Keam B; Heo DS; Han DH; Rhee CS; Kim JH; Jung KC; Wu HG
Cancer Res Treat; 2019 Oct; 51(4):1313-1323. PubMed ID: 30699498
[TBL] [Abstract][Full Text] [Related]
38. Whole-body hyperthermia combined with chemotherapy and intensity-modulated radiotherapy for treatment of advanced nasopharyngeal carcinoma: a retrospective study with propensity score matching.
Zheng N; Xu A; Lin X; Mo Z; Xie X; Huang Z; Liang Y; Cai Z; Tan J; Shao X
Int J Hyperthermia; 2021; 38(1):1304-1312. PubMed ID: 34468276
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Value of Cavernous Sinus Invasion in Patients with Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiotherapy.
Liao JF; Ma L; Du XJ; Lan M; Guo Y; Zheng L; Xia YF; Luo W
PLoS One; 2016; 11(1):e0146787. PubMed ID: 26824230
[TBL] [Abstract][Full Text] [Related]
40. The Changing Therapeutic Role of Chemo-radiotherapy for Loco-regionally Advanced Nasopharyngeal Carcinoma from Two/Three-Dimensional Radiotherapy to Intensity-Modulated Radiotherapy: A Network Meta-Analysis.
You R; Cao YS; Huang PY; Chen L; Yang Q; Liu YP; Zou X; Zhang YN; Jiang R; Zhang MX; Duan CY; Lin AH; Hong MH; Chen MY
Theranostics; 2017; 7(19):4825-4835. PubMed ID: 29187906
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
